Study Characteristics | Patients, n | Symptom Duration | Followup | Remarks |
---|---|---|---|---|
van der Linden13 | 2258 | < 2 years | 1 yr for initiation of MTX or any DMARD therapy, 5 yrs for persistent arthritis | Population-based prospective cohort |
Kaneko15 | 313 | Median 18 wks (range 1–1040) | Interval between first visit and the time of diagnosis, median 2 wks (range 1–40) | Retrospective single-center observational study |
Varache16 | 270 | < 1 yr | 2 yrs | Prospective observational cohort of patients with early arthritis from 1995 to 1997 in 7 hospitals in Brittany, France |
Britsemmer17 | 455 | < 2 yrs | At least 12 mo | Ongoing prospective cohort of early arthritis at the Jan van Breemen Institute, Amsterdam, Netherlands |
Alves18 | 231 | ≤ 12 mo | 12 mo | Ongoing, prospective, inception cohort study in the greater Rotterdam area (set up July 2004), patients who were included from 2000 onwards |
Cader14 | 265 | < 3 mo | 18 mo | Rapid access early inflammatory arthritis clinic at Sandwell and West Birmingham Hospitals NHS Trust, UK |
Evaluation Parameters | Sensitivity and Specificity | Predictive Values | Likelihood Ratio (LR) | Area Under the Curve |
---|---|---|---|---|
van der Linden13 | + | + | ||
Kaneko15 | + | + | + (only positive LR) | |
Varache16 | + | + | + | |
Britsemmer17 | + | + | + | + |
Alves18 | + | + | + | |
Cader14 | + | + | + |
Results | Sensitivity, % | Specificity, % |
---|---|---|
2010 ACR/EULAR RA classification criteria*1 | 87–97 | Not Tested |
Early arthritis | ||
van der Linden13 | 71–84 | 60–74 |
MTX initiation | 84 | 60 |
DMARD initiation | 74 | 74 |
Persistent disease | 71 | 65 |
Kaneko15 | ||
DMARD initiation | 73.5 | 47.1 |
Varache16 | 58 | 86 |
Britsemmer17 | 85–91 | 21–50 |
MTX within 1 yr | 85 | 50 |
Expert opinion | 90 | 48 |
Erosive disease at 3 yrs | 91 | 21 |
Alves18 | 69–74 | 66–72 |
MTX use | 74 | 66 |
Persistent disease | 69 | 72 |
Very early arthritis | ||
Cader14 | 62–74 | 66–78 |
At baseline | ||
MTX initiation | 68 | 72 |
DMARD initiation | 62 | 78 |
During followup | ||
MTX initiation | 74 | 66 |
DMARD initiation | 68 | 73 |
↵* Validation of the final criteria set with 3 independent cohorts that were not used in the identification of factors from phase 1. MTX: methotrexate; DMARD: disease-modifying antirheumatic drug; NHS: British National Health Service; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; RA: rheumatoid arthritis.